{"product_id":"bnr-marketing-mix","title":"(BNR) Burning Rock Biotech Limited Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Burning Rock Biotech Limited 4P's Marketing Mix Analysis explains the company’s products, pricing approach, distribution channels, and promotion tactics and shows how they drive positioning and sales. This page contains a real preview\/sample of the report so you can review style and content; purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS cancer diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s NGS cancer diagnostics support therapy selection and prognosis assessment across solid tumors and blood cancers. In 2025, the product line stayed centered on clinically used sequencing panels that help doctors match treatment to tumor biology and monitor disease risk. This broad testing reach matters because the company serves both tissue and blood-based workflows in oncology. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoCompass IO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncoCompass IO is Burning Rock Biotech Limited's liquid biopsy test in its flagship portfolio, built on circulating tumor DNA-based analysis. It is positioned for oncology decision support, helping guide treatment choices with noninvasive molecular data. As a 4P product, it stands out for clinical use, broad applicability, and fit with precision oncology workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoScreen IO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncoScreen IO is Burning Rock Biotech Limited's comprehensive pan-cancer tissue test for broad tumor profiling across cancer types. It uses tissue samples to support clinical insight, which helps guide biomarker review and treatment planning. For labs and hospitals, one tissue-based panel can reduce the need for multiple single-cancer tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eColonCore and ParpMatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eColonCore tests microsatellite instability and key GI-cancer mutations, while OncoScreen ParpMatch and OncoCompass ParpMatch focus on homologous recombination deficiency genes. Together, they support biomarker-driven oncology testing, helping match patients to targeted therapy choices.\u003c\/p\u003e\n\u003cp\u003eThese assays sit in a fast-growing precision-oncology segment, where MSI and HRD status can change treatment selection and trial eligibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eColonCore: GI cancer biomarker panel\u003c\/li\u003e\n\u003cli\u003eParpMatch: HRD-related gene testing\u003c\/li\u003e\n\u003cli\u003eSupports targeted treatment selection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMyriad myChoice and DetermaRx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s China agreements for Myriad myChoice and DetermaRx widen its tumor-testing menu and add lung cancer risk stratification for the local market. The pull is real: China’s cancer burden was about 4.8 million new cases and 2.6 million deaths in 2022, so demand for precise testing stays high.\u003c\/p\u003e\n\u003cp\u003emyChoice supports tumor testing, while DetermaRx helps assess recurrence risk in non-small cell lung cancer, which is a major use case in China. In 4P terms, this product line strengthens Product and Place by localizing advanced diagnostics for Chinese patients and hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands Burning Rock’s test menu\u003c\/li\u003e\n\u003cli\u003eTargets China’s large cancer market\u003c\/li\u003e\n\u003cli\u003eSupports lung cancer risk stratification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s 2025 Product Mix Centers on Precision Oncology Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's Product mix in 2025 stayed centered on oncology NGS tests for tissue and liquid biopsy workflows. OncoCompass IO, OncoScreen IO, and ColonCore anchor biomarker-driven treatment selection, while ParpMatch and licensed assays widen coverage in HRD, lung, and GI use cases. China's 4.8 million new cancer cases in 2022 keep demand for precise testing high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncoCompass IO\u003c\/td\u003e\n\u003ctd\u003eLiquid biopsy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncoScreen IO\u003c\/td\u003e\n\u003ctd\u003eTissue profiling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColonCore\u003c\/td\u003e\n\u003ctd\u003eGI biomarkers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific breakdown of Burning Rock Biotech Limited’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Burning Rock Biotech Limited’s 4Ps into a quick, structured snapshot that simplifies strategy review and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, government datasets, and peer-reviewed sources so investors can quickly verify Burning Rock Biotech assumptions and shorten due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuangzhou headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited is headquartered in Guangzhou, China, anchoring the Company in mainland China and keeping it close to hospitals, labs, and regulators. This base supports domestic commercialization and clinical collaboration, which matters in a market where China’s mainland accounted for the bulk of the Company’s operating footprint in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeople’s Republic of China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited keeps the People’s Republic of China as its main distribution base, with diagnostic solutions built for Chinese clinical needs and sold into that market. In 2025, China’s large oncology testing demand still made it the key geography for the Company’s core business, so market access, hospital ties, and local reimbursement drive sales more than overseas reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentral Laboratory Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCentral Laboratory Business is one of Burning Rock Biotech Limited’s operating segments, with tests run through centralized lab workflows. This lets Burning Rock serve patients nationwide without every site building full in-house sequencing capacity. In FY2025, this model still mattered most for scale, standardization, and faster access to molecular testing across China.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIn-Hospital Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s In-Hospital Business puts testing inside hospitals, so oncologists can order and review results faster at the point of care. That setup improves access for clinical oncology use and helps shorten the path from biopsy to treatment decision.\u003c\/p\u003e\n\u003cp\u003eIt also supports higher test adoption because physicians can use the service in routine hospital workflows, not through a separate outside channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloser to physicians and patients\u003c\/li\u003e\n\u003cli\u003eFaster clinical decision support\u003c\/li\u003e\n\u003cli\u003eBetter hospital-based adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma R\u0026amp;D services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Pharma Research and Development Services link the CompanyName to pharma and biotech partners, so it earns beyond routine diagnostics. This channel supports biomarker work, trial support, and translational research, which deepens long-term client ties. It is the part of the mix that turns lab capability into partner revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServes pharma and biotech clients\u003c\/li\u003e\n\u003cli\u003eSupports research and trials\u003c\/li\u003e\n\u003cli\u003eExpands revenue beyond diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s 2025 China-First Place Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited keeps its Place mix centered on mainland China, with Guangzhou as its base and China still the core market in 2025. Central laboratories widen reach nationwide, while in-hospital channels put testing closer to oncologists and patients. Pharma research services add another access point through partner labs and trial work.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadquarters\u003c\/td\u003e\n\u003ctd\u003eGuangzhou, China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain market\u003c\/td\u003e\n\u003ctd\u003eMainland China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery model\u003c\/td\u003e\n\u003ctd\u003eCentral lab + in-hospital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBurning Rock Biotech Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Burning Rock Biotech Limited 4P’s Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact same editable, high-quality document included in your order, not a sample or demo.\u003c\/p\u003e\n\u003cp\u003eBuy with confidence: no surprises, immediate download, and practical insights on Product, Price, Place, and Promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited uses clinical trial collaborations to raise scientific visibility for its assays and to support validation in real oncology settings. These partnerships help place its tests in investigator-led studies and multi-center trials, which can speed adoption by labs and cancer clinicians. In 2025\/2026, that trial-led route is especially relevant as oncology diagnostics keep shifting toward evidence-backed, locally validated use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca and Bayer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s collaborations with AstraZeneca and Bayer lift its profile with oncologists and researchers, because both names are widely trusted in cancer care. These ties add third-party credibility and help position Burning Rock as a partner in precision oncology, not just a test maker. That matters in a market where peer recognition can speed adoption and support clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson and Merck KGaA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited lists Johnson \u0026amp; Johnson and Merck KGaA as partners, and that works as indirect promotion through co-development and study work. Johnson \u0026amp; Johnson reported about $88.8 billion in 2024 sales, while Merck KGaA posted about €21.2 billion, so both names carry heavy oncology credibility. That kind of pharma-led link signals scientific relevance and can lift Burning Rock Biotech Limited's visibility with hospitals and researchers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCStone and BeiGene\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s ties with CStone and BeiGene widen its China oncology network and help speed patient recruitment for studies. They also strengthen local market access, which matters in a market where trial speed and physician reach can shape adoption. These links fit its focus on therapies with stronger clinical fit and commercial pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWider China oncology reach\u003c\/li\u003e\n\u003cli\u003eFaster study recruitment support\u003c\/li\u003e\n\u003cli\u003eStronger local market presence\u003c\/li\u003e\n\u003cli\u003eSharper therapy selection focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicense agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited uses license agreements with Myriad Genetics and Oncocyte to bring established tests into China under its own platform, so it can expand faster without building every assay from scratch. This approach supports broader brand recognition and lowers product-development risk. \u003c\/p\u003e\n\u003cp\u003eIt also helps Burning Rock sell tested, clinically known products in a market where China’s cancer burden is still rising, which keeps demand for advanced diagnostics high. Licensing is a practical route to add differentiated offerings while saving time versus full in-house development. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo key partners: Myriad Genetics and Oncocyte\u003c\/li\u003e\n\u003cli\u003eImports proven tests into China\u003c\/li\u003e\n\u003cli\u003eExpands portfolio without full R\u0026amp;D build\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock Gains Credibility Through Big Pharma Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited promotes its oncology tests mainly through trial collaborations and licensing ties that build clinician trust and give it third-party validation. Partnerships with AstraZeneca, Bayer, Johnson \u0026amp; Johnson, Merck KGaA, Myriad Genetics, and Oncocyte widen reach, support study recruitment, and help position its assays as clinically proven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003ePromotion role\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJohnson \u0026amp; Johnson\u003c\/td\u003e\n\u003ctd\u003eCredibility\u003c\/td\u003e\n\u003ctd\u003e$88.8B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck KGaA\u003c\/td\u003e\n\u003ctd\u003eCredibility\u003c\/td\u003e\n\u003ctd\u003e€21.2B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited does not publish a standard retail list price for its tests, so pricing appears to be contract-based rather than shelf-based. That fits how oncology diagnostics are usually sold to hospitals, labs, and partners, where rates depend on volume, assay type, and reimbursement terms. In its latest reported results, Burning Rock posted RMB 214.0 million in revenue for 2025, showing a B2B model where negotiated pricing matters more than public price tags.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited uses hospital contracting for in-hospital diagnostics, so price is set by procurement deals, not a fixed consumer list. Rates can change by site, test type, and order volume, which helps hospitals negotiate lower per-test costs on bigger runs. That model fits institutional buyers and supports reimbursement-linked sales, not walk-in retail pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentral lab service fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited usually charges central lab testing as a fee per assay or panel, with the final price tied to sample type, panel size, and test complexity. Liquid biopsy often costs more than tissue testing because it needs deeper sequencing and tighter quality control. In 2025, this fee model stayed the key revenue lever for central lab services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma research contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharma research contracts at Burning Rock Biotech Limited are usually priced as project deals, not fixed menus. Fees move with study scope, sample size, and how deep the analysis goes, so larger biomarker and sequencing projects cost more. In 2025, this kind of partner-led pricing stays the norm across biotech and pharma R\u0026amp;D outsourcing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProject-based pricing\u003c\/li\u003e\n\u003cli\u003eScope drives fee levels\u003c\/li\u003e\n\u003cli\u003eSample count raises cost\u003c\/li\u003e\n\u003cli\u003eNegotiated with pharma partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and reimbursement dependent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s pricing for licensed tests is licensing and reimbursement dependent, so myChoice and DetermaRx can carry different price points by market, payer, and channel. Reimbursement rules, tender terms, and local access limits can move realized net price more than list price. Exact July 2026 prices are not publicly specified in the available information.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed tests may use separate pricing.\u003c\/li\u003e\n\u003cli\u003eReimbursement can set net price.\u003c\/li\u003e\n\u003cli\u003eTenders and access shape local pricing.\u003c\/li\u003e\n\u003cli\u003eJuly 2026 prices are not disclosed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Pricing Stays Contract-Based in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s price is mostly contract-based, not public list pricing, so hospitals, labs, and pharma partners negotiate by test type, volume, and reimbursement. In 2025, revenue was RMB 214.0 million, showing pricing still depends on institutional deals. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice driver\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital contracts\u003c\/td\u003e\n\u003ctd\u003eNegotiated per site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCentral lab fees\u003c\/td\u003e\n\u003ctd\u003ePer assay or panel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma projects\u003c\/td\u003e\n\u003ctd\u003eScope-based pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed tests\u003c\/td\u003e\n\u003ctd\u003eReimbursement-led\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234149343497,"sku":"bnr-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bnr-marketing-mix.webp?v=1785713397","url":"https:\/\/dcfanalyst.com\/products\/bnr-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}